Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE: BMY) and Innate Pharma S.A. (Euronext Paris: FR0010331421, IPH) announced a global agreement for the development and commercialization of IPH2102, a novel antibody in Phase I development for the treatment of cancer.

Under the terms of the agreement, Innate Pharma will grant to Bristol-Myers Squibb exclusive worldwide rights to develop, manufacture and commercialize IPH2102 and related compounds blocking KIR receptors. The agreement covers all potential indications for IPH2102. Innate Pharma will continue to develop IPH2102 in acute myeloid leukemia (AML) through to the end of Phase II. Innate Pharma will also provide pre-clinical support for the development of IPH2102. Bristol-Myers Squibb will fund the development of IPH2102, make an upfront payment of $35 million and additional payments of up to $430 million, depending on the achievement of pre-specified milestones during the development and commercialization period, as well as pre-specified tiered double-digit royalty payments on worldwide net sales.

"Bristol-Myers Squibb is dedicated to helping patients prevail over cancer," said Francis Cuss, senior vice president, Research, Bristol-Myers Squibb. "To help us in this mission, we are very pleased to join forces with Innate Pharma which has developed a deep understanding of the immune system. Working together we have the opportunity to develop IPH2102, a potential first-in-class biologic that may be able to harness a patient's immune system in the fight against cancer."

"Bristol-Myers Squibb's String of Pearls strategy seeks to establish collaborations with leading innovator companies across the globe" said Mike Seeley, general manager, France, Bristol-Myers Squibb. "We are excited to establish an important such collaboration in France with Innate Pharma, a pioneer in the field of innate immunity. This collaboration highlights our commitment to France, the French biotech community and to immuno-oncology, an area in which Bristol-Myers Squibb has developed a robust pipeline including ipilimumab."

"This agreement is the largest biotech licensing deal ever signed in France. Entering such a collaboration with Bristol-Myers Squibb gives Innate Pharma a strong validation of the key concepts of its science", said Hervé Brailly, Chief Executive Officer, Innate Pharma. "Bristol Myers Squibb is a global leader in the field of immuno-oncology and therefore the best possible partner to fully realize the potential of IPH2102 and we look forward to this collaboration."

About IPH2102
IPH2102 is a fully human monoclonal antibody blocking interaction between Killer-cell immunoglobulin-like receptors (KIR) on Natural Killer (NK) cells with their ligands. By blocking these receptors, it facilitates activation of NK cells, and, potentially, destruction of tumor cells by the latter. It is currently being tested in a Phase I clinical trial in cancer patients.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About Innate Pharma
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs targeting innate immunity checkpoints. Its innovative approach has been validated by license agreements with Novo Nordisk A/S. and Bristol Myers Squibb, two major pharmaceutical companies.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...

Pfizer and BioNTech choose lead mRNA vaccine candi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a singl...